Funding Acknowledgements Type of funding sources: None. Introduction Intravenous double-syringe technique (DST) of adenosine administration consists of an intravenous bolus of adenosine via three-way stopcock followed by an immediate 10-20ml sodium chloride 0.9% flush and is the recommended first-line treatment for stable supraventricular tachycardia (SVT). However, an alternative single-syringe technique (SST) method for adenosine administration has been described. This consists of diluting adenosine with sodium chloride 0.9% to a total volume of 15-20ml and was recently found to be potentially beneficial in several studies. Purpose We aimed to perform a meta-analysis of the SST versus the DST of adenosine administration as treatments for SVT. Methods We systematically searched EMBASE, PubMed, Cochrane, and ClinicalTrials.gov databases for randomised controlled trials (RCTs) and non-randomised studies of intervention (NRSIs) comparing the DST to SST adenosine administration in patients with SVT. The risk of bias was assessed by RoB-2 for RCTs and ROBINS-I for NRSIs. Outcomes included termination rate, termination rate at first dose, total administered dose, adverse effects, and discharge rate. Results We included four studies (three RCTs and one NRSI) with a total of 180 (60.55% female) patients, of whom 100 (55.55%) underwent the SST of adenosine administration. The three RCTs were considered of some concerns due to no pre-specified analysis in all studies and deviation from the intended intervention in one study. The NRSI was considered to carry a serious risk of bias by no analysis method that controlled for confounding, the possible influence of the outcome measure by knowledge of the intervention received, and no pre-specified analysis. No significant difference was found between treatment groups regarding termination rate (p = 0.22, Fig 1a), termination rate restricted to RCTs (p = 0.49, Fig 1b), total administered dose (p = 0.29, Fig 2a) and discharge rate (p = 0.1, Fig 2b). Termination rate at first dose (OR 2.87; CI 1.11-7.41; p = 0.03; I² = 0%, Fig 1c) was significantly increased in patients who received the SST. Major adverse effects were observed in only one study, with one patient suffering extravasation and phlebitis in the DST group. Conclusion To our knowledge, this is the first meta-analysis studying SST versus conventional DST for the management of SVT. This study suggests that the SST may be as safe as DST, equally effective for SVT termination, or even potentially more effective with the first dose. The SST would represent a simpler and more rapid approach, obviating the need for syringe switching or three-way stopcock, and reducing the margin of error in adenosine administration. To our knowledge, this is the highest quality evidence to date. Our results demonstrate that the current evidence is sufficient to support both SST and DST. However, favouring one technique over the other is not feasible given the limited sample size.
Introduction: Deep learning (DL) has shown promising results for mammographic breast cancer diagnosis. However, the impact of artificial intelligence (AI) in the screening process have not yet been fully addressed in terms of workload reduction, which has potential to decrease healthcare disparities. Radiologists are tasked with overwhelming volumes of screening mammograms, particularly in medically underserved areas. Therefore, when applied to workflow improvement, AI might be a tool to reduce healthcare disparities. The purpose of this systematic review and meta-analysis was to assess if AI-based triaging of breast cancer screening mammograms could reduce the radiologist’s workload with non-inferior sensitivity. Methods: PubMed, EMBASE, Cochrane Central and Web of Science databases were systematically searched for studies that evaluated AI algorithms on computer-aided triage of breast cancer screening mammograms. We extracted data from homogenous studies and performed a proportion meta-analysis with random-effects model to verify the radiologist’s workload reduction and the software’s sensitivity. Results: A total of 14 studies were systematically selected. Three studies using the same commercially available DL algorithm were included in the meta-analysis, with 156852 examinations evaluated at the threshold of 8. The radiologist’s workload decreased by 68.3% (95%CI 0.655-0.711, I² = 98.76%, p < 0.001), with a sensitivity of 93.1% (95%CI 0.882-0.979, I² = 83.86%, p = 0.002). Conclusion: Our findings suggest that DL computer-aided triage of breast cancer screening mammograms significantly reduces the radiologist’s workload with high sensitivity. Although AI’s implementation remains complex and heterogeneous, it is a promising tool to optimize healthcare resources with a potential large impact in low resource settings that struggle with workforce shortage. Citation Format: Debora Xavier, Isabele A. Miyawaki, Carlos Alberto Campello Jorge, Matheus Jose Barbosa Moreira, Bruno M. Carvalho, Felipe Batalini. Artificial intelligence-based triaging of breast cancer screening mammograms and radiologist workload reduction: a systematic review and meta-analysis [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-04-06.
e13616 Background: Lung cancer remains the main cause of cancer-related mortality globally, with non-small cell (NSCLC) accounting for the majority of cases. The advent of immunotherapy (IO) has expanded treatment options for advanced NSCLC. However, there are no bibliometric studies exploring NSCLC IO-based trials. We aimed to provide a systematic and comprehensive analysis of the design, reporting, population, and disparities of phase 3 trials investigating IO for advanced NSCLC. Methods: MEDLINE search was performed (last decade) for phase 3 trials reporting on patients with advanced (stage IIIA or higher) NSCLC. We assessed relationships between study outcomes, funding transparency, conflict of interest, journal impact factor (IF), region, gender of the first and last authors, population size, and ethnicity. Results: From 2012 to 2022, 2556 articles were screened and 81 were included. Overall survival (OS), followed by progression/disease-free survival (PFS) and overall/objective response (ORR) were the most commonly reported primary endpoints, representing 54%, 44%, and 15% respectively. The majority of the studies ( > 97%) had a funding sources statement and declared COI. Male first and last authorship represented 84% and 74% of studies, respectively. In 62% of trials reporting the patient’s ethnicity, white was the most common (65%). Regarding the source of funding, 74% of trials reported industry-only, 8% academia-only, 11% combined, 4% no funding received and 2.5% were not transparent. 98% of trials were from high-income countries (HIC), being the US (37%) and China (26%) the most reported. The mean number of authors with declared COI was 10.55 [0-25] and the mean total number of authors was 21.3 [5-76]. Publications journals' mean IF was 57.7 [2.1-202.7]. COI declaration was associated with publication in a journal with a higher IF compared to studies with no declared COI (p < 0.05). The journal IF was significantly higher in the US publications compared to China (p < 0.01). Trials assessing OS and PFS as their primary outcome were published with a higher IF in relation to assessing ORR only (p < 0.05). There was a significant association between the first and last authors' gender (p < 0.05), with a higher likelihood of matching genders (OR = 4,5 [1,3-14,4]). There was no association between the proportion of COI among authors, source of funding, and first author’s gender with journal IF. Conclusions: Phase 3 trials exploring IO for advanced NSCLC are majorly done in HIC, report industry funding and COI, and have males as the first and last authors. PFS is the primary outcome of almost 50% of the trials. We identified that among the primary outcomes studied, declaration of COI and author’s geographic affiliation may influence the publication’s IF. Sustained efforts are required to guarantee impartial reporting of clinical trial results and inclusive representation.
Por ter um clima úmido a cidade de Curitiba é bastante propícia para a proliferação de mofo (bolor), um tipo de fungo. Esses bolores podem acarretar inúmeros problemas de saúde. Portanto, devido ao risco de contaminação causado pelos fungos, é necessário combatê-los. As soluções disponíveis no mercado para esse problema, entretanto, são caras e, muitas vezes, inacessíveis. Portanto, o objetivo do projeto é de melhorar a qualidade de vida da população por meio da criação de uma solução acessível, a partir das plantas "Coroa-de-Cristo" (Euphorbia sp) e "Espirradeira" (Nerium oleander)que já apresentaram efeito moluscicida e bactericida conhecidos, respectivamente. Para o teste das propriedades antifúngicas da Coroa-de-Cristo, foi utilizado seu látex. Já para o teste com a Espirradeira, foi utilizado um extrato etanólico de suas folhas. Para o meio de cultura dos fungos, foi utilizado o gel Ágar, posteriormente despejado em placas de Petri. As placas foram esterilizadas e contaminadas com bolor proliferado em pão. As substâncias foram misturadas ao meio de cultura em algumas placas de Petri, e em outras, foram aplicadas diferentes quantidades de cada substância. A fotodegradação dos compostos também foi testada. Em outro experimento, o látex foi misturado com tinta para testar se suas propriedades seriam mantidas. Também foram feitos adesivos à base de ágar em que foi aplicado o látex. Por meio desses testes, pôde-se atestar a viabilidade do uso da Espirradeira e, especialmente, da Coroa-de-Cristo como plantas com propriedades antifúngicas. Ambas as plantas se mostraram eficazes em retardar o aparecimento dos fungos e também em eliminar os fungos contaminados. Dissolvido em tinta e quando aplicado no adesivo, o látex não afetou as propriedades da tinta e sua ação
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.